Biotech Momentum Eases: September Is A Bit Sluggish
September 14, 2017 at 19:08 PM EDT
Risks for biotech stocks and the healthcare sector, in general, are with Congress: drug pricing debate and/or lack of progress on tax reform.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.